GeoVax Labs, Inc.
GOVX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GOVX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, with no approved products and a history of operating losses.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 1 clinical trial for GeoVax Labs, Inc..
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, with no approved products and a history of operating losses.
- GeoVax has no product revenue and expects to continue generating operating losses for the foreseeable future [sec · filed 2026-05-26].
- As of June 30, 2026, the company reported cash & equivalents of $3.1M, zero revenue, and a net loss of $4.4M for the quarter [latest reported financials].
- The company's independent auditors have issued a 'going concern' opinion, reflecting substantial doubt about its ability to continue operations [sec · filed 2026-04-16].
- GeoVax is advancing three clinical programs: GEO-CM04S1, Gedeptin, and GEO-MVA, with development costs expected to increase as trials progress [sec_mda · as of 2026-05-14].
What works
- GeoVax leverages third-party resources through collaborations with government, academic, and corporate entities for preclinical and clinical testing [sec · filed 2026-05-26].
- The company has a pipeline of multiple product candidates targeting infectious diseases and cancer, including GEO-CM04S1, Gedeptin, and GEO-MVA [sec_mda · as of 2026-05-14].
- GeoVax has historically secured funding through equity sales and government grants/contracts, demonstrating some ability to attract capital [sec_mda · as of 2025-11-13].
What to weigh
- GeoVax has a history of operating losses, with an accumulated deficit of approximately $21.5 million as of December 31, 2025, and expects losses to increase [sec · filed 2026-04-16].
- The company's cash runway is limited; existing cash is only sufficient into June 2026, and there is substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-14].
- GeoVax has no approved products and does not expect to generate product revenue for at least several more years [sec · filed 2026-05-26].
- The company faces significant uncertainty in securing additional financing, which may not be available on favorable terms or at all [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
GeoVax has a history of operating losses and expects losses to continue.
“We have a history of operating losses, and we expect losses to continue for the foreseeable future.”
SEC filings · May 26, 2026
Existing cash is only sufficient into June 2026.
“As of the date of this Quarterly Report, we believe that our existing cash and cash equivalents are sufficient to fund our operations into June 2026.”
SEC MD&A · May 14, 2026
The company has a going concern opinion from its auditors.
“We have received a going concern opinion from our auditors.”
SEC filings · April 16, 2026
GeoVax has no product revenue and does not expect any for several years.
“We have not generated any revenues from the sale of the products we are developing, and we do not expect to generate any such revenues for at least the next several years.”
SEC filings · May 26, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Auditors have issued a going concern opinion; cash may only last into June 2026 [sec_mda · as of 2026-05-14].
- No product revenue — Company has no approved products and no product revenue for at least several years [sec · filed 2026-05-26].
- Financing uncertainty — Additional funding may not be available on acceptable terms or at all [sec_mda · as of 2026-05-14].
- Clinical development risks — Product candidates require extensive testing and regulatory approval; may face delays or failures [sec · filed 2026-05-26].
What to watch
- Ability to raise additional capital through equity offerings, grants, or partnerships [sec_mda · as of 2026-05-14].
- Progress and data readouts from GEO-CM04S1, Gedeptin, and GEO-MVA clinical programs [sec_mda · as of 2026-05-14].
- Any changes in the going concern status or cash runway updates [sec · filed 2026-04-16].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run GeoVax Labs, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GeoVax Labs, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.8 months
D/E 1.64
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$439K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 269,253 | $372K |
| geode capital management, llc | 36,076 | $50K |
| vanguard capital management llc | 6,434 | $9K |
| vanguard fiduciary trust co | 5,068 | $7K |
| blackrock, inc. | 1,093 | $2K |
| wells fargo & company/mn | 31 | $43 |
| morgan stanley | 6 | $8 |
| danske bank a/s | 3 | $4 |
| caitong international asset management co., ltd | 2 | $3 |
| quaker wealth management, llc | 1 | $2 |
Showing top 10 of 12 institutional holders of GeoVax Labs, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.6%
- Days to cover
- 3.8
- Shares short
- 277,558
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GOVX short interestGovernance
Frequently asked questions
What is the AI investment thesis for GeoVax Labs, Inc.?
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, with no approved products and a history of operating losses.
What is GeoVax Labs, Inc.'s lead drug candidate?
GeoVax Labs, Inc.'s most advanced tracked candidate is gedeptin (Phase 2) for advanced head and neck squamous cell carcinoma (HNSCC).
Who is the CEO of GeoVax Labs, Inc.?
Mr. David Alan Dodd is the chief executive officer of GeoVax Labs, Inc. (GOVX).
Where is GeoVax Labs, Inc. headquartered?
GeoVax Labs, Inc. (GOVX) is headquartered in Smyrna, GA, United States.
What therapeutic areas does GeoVax Labs, Inc. focus on?
GeoVax Labs, Inc. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.